文献速递肿瘤 PET/CT

新型免疫PET诊疗探针在HER2阴性乳腺癌中的初步临床结果

Initial Clinical Results of a Novel Immuno-PET Theranostic Probe in Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.
PubMed 文献 · J Nucl Med · 2020-03-13

这项前瞻性研究在23例HER2阴性、CEA阳性转移性乳腺癌患者中评估了预靶向免疫PET(免疫PET)的成像性能,并与CT、骨MRI和18F-FDG PET比较。免疫PET对淋巴结和肝转移的敏感性略高于CT或18F-FDG PET,对骨病灶的敏感性高于MRI或18F-FDG PET,但肺转移敏感性较低,且能显示18F-FDG PET未显示的部分脑转移。总病灶活性免疫PET显著高于18F-FDG PET(P=0.009)。

要点

  • 免疫PET总病灶敏感性94.7%(1116/1178),18F-FDG PET为89.6%(1056/1178)。
  • 免疫PET骨病灶敏感性95.8%,高于MRI的90.7%和18F-FDG PET的89.3%。
  • 免疫PET肺转移敏感性48.3%,低于CT的100%和18F-FDG PET的75.9%。

核心结论

  • 使用抗CEA/抗IMP288双特异性抗体后给予68Ga-IMP288的免疫PET,是一种对HER2阴性、CEA阳性转移性乳腺癌患者具有潜在敏感性的诊疗成像方法,值得进一步研究。

研究设计与样本

  • 前瞻性研究,纳入23例HER2阴性、CEA阳性转移性乳腺癌患者。
  • 患者接受150 MBq 68Ga-IMP288全身免疫PET,金标准为组织学和影像随访。

主要发现

  • 免疫PET与18F-FDG PET的总病灶敏感性分别为94.7%(1116/1178)和89.6%(1056/1178)。
  • 淋巴结转移敏感性:免疫PET 92.4%,CT 69.7%,18F-FDG PET 89.4%。
  • 肝转移敏感性:免疫PET 97.3%,CT 92.1%,18F-FDG PET 94.8%。
  • 肺转移敏感性:免疫PET 48.3%,CT 100%,18F-FDG PET 75.9%。
  • 骨病灶敏感性:免疫PET 95.8%,MRI 90.7%,18F-FDG PET 89.3%;免疫PET可显示18F-FDG PET未显示的脑转移。

关键数值与推荐

  • 免疫PET与18F-FDG PET的肿瘤SUVmax、SUVmean和总肿瘤体积相当,但免疫PET的总病灶活性显著更高(P=0.009)。

局限性

  • 原文结论指出该免疫PET方法值得进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This prospective study evaluated the imaging performance of a novel pretargeting immunologic PET (immuno-PET) method in patients with human epidermal growth factor receptor 2 (HER2)-negative, carcinoembryonic antigen (CEA)-positive metastatic breast cancer, compared with CT, bone MRI, and 18F-FDG PET. Methods: Twenty-three patients underwent whole-body immuno-PET after injection of 150 MBq of 68Ga-IMP288, a histamine-succinyl-glycine peptide given after initial targeting of a trivalent anti-CEA, bispecific, antipeptide antibody. The gold standards were histology and imaging follow-up. Tumor SUVs (SUVmax and SUVmean) were measured, and tumor burden was analyzed using total tumor volume and total lesion activity. Results: The total lesion sensitivity of immuno-PET and 18F-FDG PET were 94.7% (1,116/1,178) and 89.6% (1,056/1,178), respectively. Immuno-PET had a somewhat higher sensitivity than CT or 18F-FDG PET in lymph nodes (92.4% vs. 69.7% and 89.4%, respectively) and liver metastases (97.3% vs. 92.1% and 94.8%, respectively), whereas sensitivity was lower for lung metastases (48.3% vs. 100% and 75.9%, respectively). Immuno-PET showed higher sensitivity than MRI or 18F-FDG PET for bone lesions (95.8% vs. 90.7% and 89.3%, respectively). In contrast to 18F-FDG PET, immuno-PET disclosed brain metastases. Despite equivalent tumor SUVmax, SUVmean, and total tumor volume, total lesion activity was significantly higher with immuno-PET than with 18F-FDG PET (P = 0.009). Conclusion: Immuno-PET using anti-CEA/anti-IMP288 bispecific antibody, followed by 68Ga-IMP288, is a potentially sensitive theranostic imaging method for HER2-negative, CEA-positive metastatic breast cancer patients and warrants further research.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Rousseau C, Goldenberg DM, Colombié M, et al. Initial Clinical Results of a Novel Immuno-PET Theranostic Probe in Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer. J Nucl Med. 2020. PMID: 32169921. doi:10.2967/jnumed.119.236000

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。